New Delhi: Strides Phaarma has developed and commercialised Favipiravir antiviral tablets and stressed that the drug has gives positive outcomes in COVID-19 treatment globally.
“The drug has demonstrated positive outcomes, including a reduction in the duration of COVID-19 and improved lung conditions for the patients,” the company said. The product is a generic version of Avigan of Toyama Chemical, Japan.
“Strides is the first Indian company to have commenced export of Favipiravir tablets. The company said it will immediately apply to Indian Drug Authorities to commence necessary studies and make the drug available to Indian patients expeditiously. Strides has developed Favipiravir tablets in 400mg and 200mg strengths for convenient dosage administration.”
Export process is currently taken place to Gulf Cooperation Council (GCC) countries to treat patients under their treatment programme for COVID-19.
“The partner has already commercialised the Favipiravir API from its USFDA, KFDA, PMDA and WHO approved manufacturing facility and has capabilities to manufacture the Favipiravir API from its Key Starting Material (KSM) in-house,” Strides said.
“We are pleased to be the First Indian company to develop and commercially launch Favipiravir tablets for the global markets. This development reinforces our commitment to play a substantial role in the society by bringing affordable and quality healthcare to millions of people around the globe.” Company’s CEO and MD R Ananthanarayanan said.
“Favipiravir is a complex drug to make, while we are manufacturing the tablets in-house, we are also excited to partner with the API manufacturer such that our supply chain remains secured up to the key starting material,” he further added.
